TickerFacts.

Avalo Therapeutics, Inc. (AVTX): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

Older than the company's other figures. The latest Free Cash Flow is for the year ended 2022-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Capital Expenditures, which Free Cash Flow is computed from, under the concepts TickerFacts maps.

-$26.85M
Year ended 2022-12-31
$12.56M2013-12-31: -$11.51M2014-12-31: -$15.54M2015-12-31: -$10.18M2016-12-31: -$14.61M2017-12-31: $12.56M2018-12-31: -$3.69M2019-12-31: -$19.40M2020-12-31: -$40.60M2021-12-31: -$71.00M2022-12-31: -$26.85M-$26.85M
2013-12-31 Free Cash Flow (USD) 2022-12-31
Period endedFree Cash FlowChange YoYSource filing
2022-12-31-$26.85Mn/m2024-03-29, From 2022-01-01
2021-12-31-$71.00Mn/m2023-03-29, From 2021-01-01
2020-12-31-$40.60Mn/m2022-03-02, From 2020-01-01
2019-12-31-$19.40Mn/m2021-03-08, From 2019-01-01
2018-12-31-$3.69Mn/m2020-03-11, From 2018-01-01
2017-12-31$12.56Mn/m2019-03-18, From 2017-01-01
2016-12-31-$14.61Mn/m2018-04-02, From 2016-01-01
2015-12-31-$10.18Mn/m2018-04-02, From 2015-01-01
2014-12-31-$15.54Mn/m2017-03-14, From 2014-01-01
2013-12-31-$11.51Mn/a2016-03-23, From 2013-01-01